Progress of Immunotherapies in Parkinson's Disease
Parkinson's disease (PD) is caused by an immune disorder triggered by α‐synuclein, leading to a persistent neuroinflammatory cycle that drives the disease from non‐motor symptoms to the motor stage. Second, it presents active and passive immunotherapy strategies targeting α‐synuclein and their potential in slowing down the disease progression.
Yong Peng +10 more
wiley +1 more source
Opening new frontiers with catalytic nucleic acids in miRNA inhibition. [PDF]
Patutina O +3 more
europepmc +1 more source
Heterobifunctional cross-linker with dinitroimidazole and azide modules for protein and oligonucleotide functionalization. [PDF]
Luo Q +6 more
europepmc +1 more source
Targeting <i>carA</i> Using Optimized Antisense Peptide Nucleic Acid-Cell-Penetrating Peptide Conjugates in <i>Acinetobacter baumannii</i>: A Novel Antibacterial Approach. [PDF]
Seo JH +4 more
europepmc +1 more source
Recent Advances in Nucleic Acid-Based Electrochemical Sensors for the Detection of Food Allergens. [PDF]
Fortunati S, Nazir S, Giannetto M.
europepmc +1 more source
Single-Molecule Protein Interactions and Unfolding Revealed by Plasmon-Enhanced Fluorescence. [PDF]
Teeuwen RWH +3 more
europepmc +1 more source
Rapid, Single-Step Monitoring of Monoclonal Antibody Bioavailability by Using a TNF-α-Based Multiepitope DNA Nanoswitch. [PDF]
Di Lena D +9 more
europepmc +1 more source
Following the central dogma: Nanopore sequencing from DNA and RNA to proteins. [PDF]
Wang Y +7 more
europepmc +1 more source
Intradermal delivery of lipophilic siRNAs enables prolonged skin retention and sustained gene silencing in a porcine model. [PDF]
Fakih HH +21 more
europepmc +1 more source

